Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
Authors:
Top Cited Papers
Open Access
- 1 February 2019
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (2) , e188006
Abstract
Prostate cancer (PCa) is the leading cause of cancer treatment–related years lived with disability worldwide, reflecting the confluence of its high incidence, high cure rate, and treatment-associated morbidity.1 Most patients with PCa in the developed world receive a diagnosis of clinically localized disease, and the majority have low-risk or intermediate-risk disease as defined by the National Comprehensive Cancer Network (NCCN).2 Multiple management options are available, including definitive external beam radiotherapy (EBRT), radical prostatectomy, brachytherapy, and (for patients with low-risk and favorable intermediate-risk disease) active surveillance.Keywords
This publication has 33 references indexed in Scilit:
- Stereotactic Body Radiotherapy as Treatment for Organ Confined Low- and Intermediate-Risk Prostate Carcinoma, a 7-Year StudyFrontiers in Oncology, 2014
- Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Less Cost at the Expense of More Genitourinary Toxicity Is a Concerning But Testable HypothesisJournal of Clinical Oncology, 2014
- Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy for Prostate Cancer: Comparison of ToxicityJournal of Clinical Oncology, 2014
- A New Risk Classification System for Therapeutic Decision Making with Intermediate-risk Prostate Cancer Patients Undergoing Dose-escalated External-beam Radiation TherapyEuropean Urology, 2013
- Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trialsRadiotherapy and Oncology, 2013
- Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regionsThe Lancet, 2012
- Hypofractionated stereotactic body radiotherapy in low‐risk prostate adenocarcinomaCancer, 2011
- Choice and Interpretation of Statistical Tests Used When Competing Risks Are PresentJournal of Clinical Oncology, 2008
- Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial resultsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus ConferenceInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006